Literature DB >> 8387645

Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53.

D H Mack1, J Vartikar, J M Pipas, L A Laimins.   

Abstract

The p53 protein is apparently central to the development of human cancers because both alleles are often found to be mutated in different tumour types. In addition, wild-type p53 can inhibit transformation by viral and cellular oncogenes in vitro, so p53 has been classified as a tumour suppressor. Investigations of the normal function of p53 have indicated that at least one of its functions could involve the activation of gene expression through the binding of specific DNA-regulatory sequences. Also, overexpression of p53 can mediate growth arrest and repress transcription from a variety of promoters. We demonstrate here both in vivo and in vitro that expression of wild-type p53 specifically represses the activity of promoters whose initiation is dependent on the presence of a TATA box. Promoters whose accurate transcription is directed by a pyrimidine-rich initiator element, however, are immune to the effects of p53. Furthermore, we observe that repression is mediated by an interaction of p53 with basal transcription factor(s). Thus, p53 appears to repress the activity of certain promoters through direct communication with TATA box-dependent basal transcription machinery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387645     DOI: 10.1038/363281a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  97 in total

1.  The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.

Authors:  C Gobert; A Skladanowski; A K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Transcriptional cofactor CA150 regulates RNA polymerase II elongation in a TATA-box-dependent manner.

Authors:  C Suñé; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

3.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.

Authors:  R Zhao; K Gish; M Murphy; Y Yin; D Notterman; W H Hoffman; E Tom; D H Mack; A J Levine
Journal:  Genes Dev       Date:  2000-04-15       Impact factor: 11.361

4.  The tumour suppressor protein p53 can repress transcription of cyclin B.

Authors:  K Krause; M Wasner; W Reinhard; U Haugwitz; C L Dohna; J Mössner; K Engeland
Journal:  Nucleic Acids Res       Date:  2000-11-15       Impact factor: 16.971

Review 5.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

6.  Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo.

Authors:  E A Komarova; M V Chernov; R Franks; K Wang; G Armin; C R Zelnick; D M Chin; S S Bacus; G R Stark; A V Gudkov
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

7.  Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53.

Authors:  Y Wu; H Huang; Z Miner; M Kulesz-Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

8.  Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.

Authors:  C Kunz; S Pebler; J Otte; D von der Ahe
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

9.  Transcription stimulation of the adenovirus type 12 E1a gene in vitro by the 266-amino-acid E1A protein.

Authors:  H Kawamura; N Wada; Y Makino; T A Tamura; S Koikeda; K Shiroki; Y Masamune; Y Nakanishi
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  An apoptotic defect in lens differentiation caused by human p53 is rescued by a mutant allele.

Authors:  T Nakamura; J G Pichel; L Williams-Simons; H Westphal
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.